HLS Therapeutics近日宣布,其创新药物Nilemdotm(Bempedoic Acid)已正式登陆加拿大市场。该药物专为心血管疾病风险患者设计,旨在有效降低其低密度脂蛋白胆固醇(LDL-C)水平。这一进展为加拿大高危患者提供了新的治疗选择,有望帮助改善其心血管健康管理。
HLS Therapeutics近日宣布,其创新药物Nilemdotm(Bempedoic Acid)已正式登陆加拿大市场。该药物专为心血管疾病风险患者设计,旨在有效降低其低密度脂蛋白胆固醇(LDL-C)水平。这一进展为加拿大高危患者提供了新的治疗选择,有望帮助改善其心血管健康管理。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.